$2.64
+0.08 (+3.13%)
Open$2.59
Previous Close$2.56
Day High$2.67
Day Low$2.58
52W High$31.38
52W Low$14.16
Volume—
Avg Volume293.9K
Market Cap29.53M
P/E Ratio—
EPS$-1.13
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+884.1% upside
Current
$2.64
$2.64
Target
$25.98
$25.98
$20.93
$25.98 avg
$39.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.75M | 4.21M | 3.91M |
| Net Income | 909.1K | 778.9K | 578.2K |
| Profit Margin | 19.1% | 18.5% | 14.8% |
| EBITDA | 1.38M | 1.12M | 1.11M |
| Free Cash Flow | 932.9K | 1.05M | 869.6K |
| Rev Growth | +21.8% | +17.5% | +9.1% |
| Debt/Equity | 0.24 | 0.30 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |